MRNA gene expression correlates with histologically diagnosed chemotherapy-induced hepatic injury

HPB

Volumn 13, Issue 11, 2011, Pages 811-816

  Pilgrim, Charles H C ^a,b,c   Brettingham Moore, Kate ^a   Pham, Alan ^c   Murray, William ^a   Link, Emma ^a   Smith, Marty ^c   Usatoff, Val ^c   Evans, Peter M ^c   Banting, Simon ^a,b   Thomson, Benjamin N ^a   Michael, Michael ^a,b   Phillips, Wayne A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ALFRED HOSPITAL   (Australia)

Author keywords

basic science < liver; chemotherapy < liver; colorectal metastases < liver

Indexed keywords

DIHYDROPYRIMIDINE DEHYDROGENASE; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; IRINOTECAN; MESSENGER RNA; OXALIPLATIN; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ARTICLE; CANCER CHEMOTHERAPY; CORRELATION ANALYSIS; FATTY LIVER; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER INJURY; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STEATOSIS; TOXIC HEPATITIS;

EID: 80054825664     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2011.00365.x     Document Type: Article

References (29)

1. Zorzi D, Laurent A, Pawlik TM, Lauwers GY, Vauthey JN, Abdalla EK,. (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94: 274-286. (Pubitemid 46423843)
2. McCormack L, Petrowsky H, Jochum W, Furrer K, Clavien PA., (2007) Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 245: 923-930. (Pubitemid 46809294)
3. Gomez D, Malik HZ, Bonney GK, Wong V, Toogood GJ, Lodge JP, et al,. (2007) Steatosis predicts postoperative morbidity following hepatic resection for colorectal metastasis. Br J Surg 94: 1395-1402. (Pubitemid 350144389)
4. Kooby DA, Fong Y, Suriawinata A, Gonen M, Allen PJ, Klimstra DS, et al,. (2003) Impact of steatosis on perioperative outcome following hepatic resection. J Gastrointest Surg 7: 1034-1044. (Pubitemid 37524071)
5. Garcea G, Maddern GJ,. (2008) Liver failure after major hepatic resection. J Hepatobiliary Pancreat Surg. Published online only.
6. Behrns KE, Tsiotos GG, DeSouza NF, Krishna MK, Ludwig J, Nagorney DM., (1998) Hepatic steatosis as a potential risk factor for major hepatic resection. J Gastrointest Surg 2: 292-298. (Pubitemid 128409616)
7. Marcos A, Fisher RA, Ham JM, Shiffman ML, Sanyal AJ, Luketic VA, et al,. (2000) Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation 69: 1375-1379. (Pubitemid 30238727)
8. Sahajpal A, Vollmer CM, Jr, Dixon E, Chan EK, Wei A, Cattral MS, et al,. (2007) Chemotherapy for colorectal cancer prior to liver resection for colorectal cancer hepatic metastases does not adversely affect peri-operative outcomes. J Surg Oncol 95: 22-27. (Pubitemid 46122713)
9. Bilchik AJ, Poston G, Curley SA, Strasberg S, Saltz L, Adam R, et al,. (2005) Neoadjuvant chemotherapy for metastatic colon cancer: a cautionary note. J Clin Oncol 23: 9073-9078.
10. Fernandez FG, Ritter J, Goodwin JW, Linehan DC, Hawkins WG, Strasberg SM,. (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200: 845-853. (Pubitemid 40744790)
11. Vauthey JN, Pawlik TM, Ribero D, Wu TT, Zorzi D, Hoff PM, et al,. (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24: 2065-2072. (Pubitemid 46622116)
12. Nakano H, Oussoultzoglou E, Rosso E, Casnedi S, Chenard-Neu MP, Dufour P, et al,. (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247: 118-124.
13. Karoui M, Penna C, Amin-Hashem M, Mitry E, Benoist S, Franc B, et al,. (2006) Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases. Ann Surg 243: 1-7. (Pubitemid 43054046)
14. Rubbia-Brandt L, Audard V, Sartoretti P, Roth AD, Brezault C, Le Charpentier M, et al,. (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15: 460-466. (Pubitemid 38444550)
15. Aloia T, Sebagh M, Plasse M, Karam V, Levi F, Giacchetti S, et al,. (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24: 4983-4990. (Pubitemid 46631400)
16. Schwab M, Zanger UM, Marx C, Schaeffeler E, Klein K, Dippon J, et al,. (2008) Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 26: 2131-2138.
17. Lecomte T, Landi B, Beaune P, Laurent-Puig P, Loriot MA., (2006) Glutathione S-transferase P1 polymorphism (Ile105Val) predicts cumulative neuropathy in patients receiving oxaliplatin-based chemotherapy. Clin Cancer Res 12: 3050-3056. (Pubitemid 43837350)
18. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, et al,. (2001) ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 19: 4298-4304. (Pubitemid 33096777)
19. Lunn RM, Helzlsouer KJ, Parshad R, Umbach DM, Harris EL, Sanford KK, et al,. (2000) XPD polymorphisms: effects on DNA repair proficiency. Carcinogenesis 21: 551-555. (Pubitemid 30214005)
20. van Kuilenburg AB, Meinsma R, Zonnenberg BA, Zoetekouw L, Baas F, Matsuda K, et al,. (2003) Dihydropyrimidinase deficiency and severe 5-fluorouracil toxicity. Clin Cancer Res 9: 4363-4367. (Pubitemid 37248392)
21. van Kuilenburg AB., (2004) Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur J Cancer 40: 939-950. (Pubitemid 38496249)
22. Maring JG, Groen HJ, Wachters FM, Uges DR, de Vries EG., (2005) Genetic factors influencing pyrimidine-antagonist chemotherapy. Pharmacogenomics J 5: 226-243. (Pubitemid 41131715)
23. Mendler MH, Kanel G, Govindarajan S,. (2005) Proposal for a histological scoring and grading system for non-alcoholic fatty liver disease. Liver Int 25: 294-304.
24. Hussaini SH, Farrington EA,. (2007) Idiosyncratic drug-induced liver injury: an overview. Expert Opin Drug Saf 6: 673-684. (Pubitemid 351308279)
25. Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al,. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3:RESEARCH0034.
26. van Kuilenburg AB, Haasjes J, Richel DJ, Zoetekouw L, Van Lenthe H, De Abreu RA, et al,. (2000) Clinical implications of dihydropyrimidine dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: identification of new mutations in the DPD gene. Clin Cancer Res 6: 4705-4712. (Pubitemid 32110408)
27. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH., (2002) High prevalence of the IVS14 + 1G>A mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-associated toxicity. Pharmacogenetics 12: 555-558. (Pubitemid 35177085)
28. Salt WB, 2nd,. (2004) Nonalcoholic fatty liver disease (NAFLD): a comprehensive review. J Insur Med 36: 27-41.
29. Popat S, Matakidou A, Houlston RS,. (2004) Thymidylate synthase expression and prognosis in colorectal cancer: a systematic review and meta-analysis. J Clin Oncol 22: 529-536. (Pubitemid 41079782)